Sotorasib plus panitumumab, according to an approach of dual KRAS G12C and EGFR blockade, overcame treatment resistance in patients with colorectal cancer with KRAS G12C mutation, typically a population not responding to EGFR inhibitors, such as cetuximab and panitumumab [112,113]. Here, KRAS is linked to colorectal cancer.